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Assessment of clinical benefit of systemic treatments of rare diseases including gastro-
enteropancreatic neuroendocrine tumors (GEP-NET) is challenging. Recently several 
tools have been developed to grade clinical benefit of cancer drugs. European Society 
for Medical Oncology (ESMO) has developed the ESMO Magnitude of Clinical Benefit 
Scale (ESMO-MCBS). The American Society of Clinical Oncology (ASCO) developed 
and revised the ASCO framework consisting of the Net Health Benefit (NHB) score 
juxtaposed against the costs of the treatment. In this review we graded systemic treat-
ments for GEP-NET patients with both frameworks. 
Methods
The electronic databases (PubMed, Embase) were searched for papers reporting 
comparative trials, conducted in adult GEP-NET patients in the English language. 
Papers were assessed according to the ESMO-MCBS and the NHB part of the ASCO 
revised Framework (NHB-ASCO-F) by 4 independent assessors, discrepancies were 
discussed.
Results
The search yielded 32 trials of which 6 trials were eligible for grading with the ESMO-MCBS 
resulting in scores of 2 or 3. Eight trials were eligible for grading with the NHB-ASCO-F; 
resulting in scores between 37.6 and 57.4. Trials that were not primary assessable by the 
tools were analyzed separately. Consensus between assessors was reached in 68% of 
trials with the ESMO-MCBS and in 23% of trials with the NHB-ASCO-F. 
Conclusion
The currently used systemic treatments for GEP-NET patients had low scores accord-
ing to the NHB-ASCO-F and none could be graded as meaningful clinical beneficial 
according to the ESMO-MCBS. Despite the low incidence, the heterogeneous patient 
population and relatively long natural course of NET, future studies on new treatment 
modalities should aim for high clinical benefit outcomes. 
Keywords: ESMO-MCBS, ASCO, pancreatic and gastro-intestinal, neuroendocrine 
tumors, clinical benefit, value
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Introduction 
Neuroendocrine tumors are rare malignancies with an incidence of 3.5/100,000 per 
year and a prevalence of 21.6/100,000 in the last decade (1). Median survival time is 
77 months in patients with regional and 24 months in patients with distant metastatic 
pancreatic NET (pNET) and 105 months and 56 months in case of respectively regional 
and distant metastatic intestinal NET disease (2). GEP-NET patients are frequently 
metastasized at the time of initial diagnosis. Surgery is the only curative treatment. 
Non-curative systemic treatment options include somatostatin analogues (SSA), che-
motherapy, targeted agents, and peptide receptor radionuclide therapy (PRRT) with 
variable, limited success (3-12).
Ideally, in clinical trials investigating novel drugs, the primary aim should be to study 
endpoints such as the overall survival (OS), quality of life (QoL) and treatment toxicity. 
However, for trials investigating new agents in GEP-NET patients, survival analysis can 
be challenging as the prolonged (natural) course of the disease often results in trials al-
lowing crossover towards the experimental arm, which influences OS. Crossover to the 
experimental arm or to second line therapies has impact on OS data (13). Therefore, 
progression-free survival (PFS) was recommended as a feasible and relevant primary 
end point for both, phase II and III trials in GEP-NET, by the expert consensus report 
of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting 
(13).
Recently, among others, ESMO has developed a validated and reproducible tool to 
assess the magnitude of clinical benefit for drugs for solid tumors, the ESMO-MCBS 
(14). The ASCO developed the ASCO framework for solid tumors and haematological 
malignancies consisting of the NHB score juxtaposed against the costs of the treatment 
(15,16). Both tools have been applied in several solid malignancies (14-18). However, 
the ASCO framework was assessed only in a few studies. Treatments for GEP-NET 
are not yet evaluated using the tools. In this review we therefore investigated the value 
of current systemic antitumor treatments for GEP-NET patients and their eligibility for 
grading with both ESMO-MCBS and NHB-ASCO-F. 
Methods
Search strategy
For detailed description of methods see supplementary data. In brief, trials were 
searched between Aug 1st 2015 to Jan 31th 2016, in the databases PubMed and EM-
BASE. The articles that were found, were screened using title and abstract to select 
trials published in the English language and comparing systemic treatment modalities 
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for the treatment of GEP-NET in humans. Furthermore the reference lists of national 
and international guidelines, included trials and conference abstracts were reviewed for 
additional relevant articles. 
Selection criteria for trials
Comparative trials investigating systemic antitumor treatment for well-differentiated 
GEP-NET patients were analyzed. Studies in patients with grade 3 neuroendocrine 
neoplasms were not included. Criteria for assessment are summarized in Table S1. Tri-
als were selected if at least 50 % of participants were diagnosed with GEP-NET, and the 
other participants had a NET of unknown or other origin. Abstracts were not included.
ESMO-MCBS and the NHB-ASCO-F
ESMO-MCBS grades, in the non-curative setting, range from 1-5, with grade 4 and 5 
representing meaningful clinical benefit (14). The NHB-ASCO-F ranges from -20 to 180, 
with a higher score representing a better score, no cut-off value was provided to define 
clinical benefit (15,16,18). All relevant comparative trials were assessed according to 
both tools. Relevant trials that did not meet all criteria as mentioned in Table S1 were 
assessed separately, based on the available data. 
Assessment of trials
Four members from all Dutch European Neuroendocrine Tumor Society (ENETS) cen-
tres of excellence independently scored the trials according to the ESMO-MCBS and 
the NHB-ASCO-F. After obtaining scores of these assessors we noticed a wide variation 
in results. During a consensus meeting additional agreements were defined. Next, trials 
were assessed again according to the additional agreements. The number of trials to 
which the same score was awarded between three or four assessors was registered 
after each of the two scoring sessions. Two phase III trials were published after the 
consensus meeting and were assessed according our agreements (8,12). Therefore an 
additional assessment session was not necessary for these trials.
Results
Trial selection and characterization 
The primary search strategy yielded 1,942 potentially relevant papers, of which 1,676 
remained when duplicates were discarded (Figure S1). After screening of title and 
abstract, 223 papers were preselected evaluating systemic antitumor treatment for 
GEP-NET patients.
221
Clinical benefit of systemic treatment in patients with advanced pancreatic and gastro intestinal 
neuroendocrine tumors according to ESMO-MCBS and ASCO framework
Thirty nine papers in which 35 comparative trials in GEP-NET patients were described 
were selected for further analysis. Nine trials fulfilled all criteria as summarized in Table 
S1 and were assessable according to the ESMO-MCBS and the NHB-ASCO-F (Table 
1) (3-12). Only one trial, the RADIANT-4, described in their protocol that crossover was 
not allowed (10,11). None of the trials investigated adjuvant treatment in GEP-NET or 
had a curative intent. 
The other 26 comparative trials, investigating systemic treatment in GEP-NET patients, 
did not meet all criteria for assessment with both tools (Table S1), or evaluated partici-
pants of which less than 50% had a GEP-NET. Main difficulties for assessment with 
the tools were summarized in Figure S2. As currently used national and international 
guidelines are based upon these trials, we analyzed them separately with the available 
data (Table S2, supplementary data; references). 
Assessment according to the ESMO-MCBS
Six trials were assessable with the ESMO-MCBS. The calculated score ranged from 
2 to 3 corresponding with a low level of clinical benefit. RADIANT-3 and RADIANT-4 
analyzed everolimus versus placebo in pNET and non-functional advanced NET, re-
spectively (9-11). Application of ESMO-MCBS for RADIANT-3 and RADIANT-4 resulted 
in a preliminary score of 3 reflecting a longer PFS. A hazard ratio with a lower limit of the 
95% confidence interval ≤ 0.65 for PFS determined the preliminary score. No significant 
difference in important adverse events as compared to the placebo control arm was 
detected. QoL of everolimus in pNET patients was reported in a recent abstract which 
described a single-arm phase IV study, performed in patients who started with evero-
limus (19). After 6 months, no improvement in QoL was detected. Because this was a 
single-arm study and the ESMO-MCBS could only be applied to comparative outcome 
studies, the preliminary score of the RADIANT-3 will not be downgraded, despite lack of 
improvement of QoL, when these data are published in full-report. QoL of RADIANT-4 
trial was reported in a post-hoc analysis and recently published (11). No improvement of 
QoL by everolimus versus the control arm was demonstrated. Therefore the preliminary 
score of the RADIANT-4 was downgraded to a final score 2. The NETTER-1 trial inves-
tigated 177Lu-dotatate with octreotide LAR versus octreotide LAR alone in patients with 
metastatic midgut NET (8). The calculated ESMO-MCBS score was 3, which implies a 
longer PFS in the intervention group as compared with control arm. Furthermore, there 
was no significant difference in important adverse events as compared to the control 
arm and no QoL data were documented. In the CLARINET trial GEP-NET patients or 
patients with NET of unknown origin were treated with lanreotide in the intervention 
arm versus placebo in the control arm (3). This trial showed an improvement in PFS. 
Data of QoL did not show an improvement in QoL for the intervention group, resulting 
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randomized between octreotide LAR and placebo (7). Further enrolment was stopped 
after inclusion of 85 patients instead of the planned 162 patients, because of observed 
positive effects of octreotide LAR on tumor growth and a slow recruitment rate. This trial 
resulted in an ESMO-MCBS score of 2. The trial reported by Raymond et al. analyzed 
sunitinib versus placebo in patients with progressive, advanced pancreatic NET (6). Ap-
plication of ESMO-MCBS resulted in a score of 2. An improvement in PFS was shown. 
Because reported QoL data did not show improvement, the preliminary score of 3 had 
to be downgraded one point. This trial had an early closure after randomization of 171 
patients, as observed and recommended by the safety monitoring board due to more 
serious adverse events and a higher frequency of death in the placebo group as well 
as a difference in PFS favoring sunitinib. The trial analyzing SSA and interferon versus 
SSA and bevacizumab, in advanced NET patients with progression or other poor prog-
nostic features, showed no significant difference in its primary endpoint PFS (12). The 
RADIANT-2 analyzed everolimus with long acting octreotide in advanced NET tumor 
patients associated with carcinoid syndrome (5). The PFS with a hazard ratio of 0.77 
(0.59-1.00) did not show a statistically significant clinical benefit. The trial analyzing 
capecitabine and streptozocin with or without cisplatin did also not show a statistically 
significant clinical benefit (4). Furthermore in these trials no improvement in toxicity, 
Qol, or OS was seen, and therefore the ESMO-MCBS was not applicable .
Consensus in the ESMO-MCBS score was reached in 2 of 6 trials after the first scor-
ing session (3-7,9-11). The variation in awarded scores was related to differences in 
interpretation of data, like the significance of the primary endpoint, and adjustment of 
the preliminary score for lack of improvement in QoL. After the second scoring session 
consensus was reached in 4 of 6 trials (3-7,9-11).
 Assessment according to the NHB-ASCO-F
Nine trials were assessable for the NHB-ASCO-F (3-12). The CBS varied from 0 to 63.8. 
In the trial reported by Raymond et al. and the RADIANT-3 and RADIANT-4 trials the 
treatment arm experienced more adverse events, resulting in a toxicity score of -5 and 
-20, respectively (6,9-11). Bonus points were awarded for long term disease control; if, 
at a time point that was twice the median PFS for the control regimen, the percentage 
of patients having PFS was at least 50% higher for the intervention arm compared with 
the control arm, to the trial reported by Raymond et al, PROMID-trial, RADIANT-4, 
RADIANT-3 and the NETTER-1 (6-11).  No consensus was obtained for the score of 
the trials assessed by the NHB-ASCO-F after 2 scoring sessions. This was generally 
related to discrepancies in interpretation of toxicity score. Finally, after an additional 
discussion in 4 trials consensus was obtained for NHB and in 5 trials consensus was 




To define the clinical benefit of systemic antitumor treatment in GEP-NET patients, we 
systematically applied the ESMO-MCBS and the NHB-ASCO-F to relevant trials. Six 
out of 35 trials fulfilled all requirements to be assessed with the ESMO-MCBS resulting 
in an ESMO-MCBS score of 2 or 3, while 9 trials could be assessed with the NHB-
ASCO-F and resulted in scores between 37.6 to 57.4. No clear cut-off value to define 
clinical benefit with the ASCO framework was provided (15,16). None of the trials that 
were included in our analysis could demonstrate a meaningful clinical benefit according 
to the employed tools. The ESMO-MCBS scores were generally lower than in other 
tumor types, like metastasized breast or colorectal cancer (14,17). In more common 
tumor types, sufficient numbers of patients can be included in trials powered to detect 
a difference in OS between the intervention and control group. In NET, such large trials 
are scarce. In addition, OS difference detection is challenging in NET patients. There-
fore, PFS is a frequently used, primary endpoint in NET trials. An improvement in PFS 
has less impact compared to OS in the ESMO-MCBS scores and the NHB-ASCO-F. 
Furthermore, none of the assessable trials in GEP-NET, showed an improvement in 
QoL or less toxicity as compared to the control arm. Therefore, these outcomes did not 
result in an upgrade of the preliminary score in the ESMO-MCBS. 
Ideally OS and QoL should be the primary endpoint of all trials with new drugs (20). 
This is challenging in NET. Reasons for this include the heterogeneous patient popu-
lation, the long natural course of the disease and the wide variability of subsequent 
lines of therapy after progression. The heterogeneity of the patients composing the 
NET population is important to take into account. This illustrates the importance of 
well-defined inclusion criteria. The eligibility criteria of the RADIANT-2 trial included 
patients with; serotonin producing NET and progressive, low- or intermediate-grade 
and advanced disease (5). Despite these clear criteria still large variation in patient and 
tumor characteristics between patients exists. Despite the randomized design of the 
trial, this could have influenced PFS. 
Current guidelines for GEP-NET anti-tumor treatment are based on clinical trials and 
on expert opinion. These guidelines influence our daily clinical practice. Therefore, we 
also assessed trials that could not be fully assessed by the ESMO-MCBS and ASCO 
framework (table S2). The control arms of trials analyzing chemotherapy included 
interferon, dacarbazine, and other kinds of chemotherapy, respectively. Given current 
knowledge about the effects of chemotherapy, the control arm, nowadays, likely would 
not have contained chemotherapy. With this analysis we demonstrated, that current 
guidelines are partially based on studies not powered to determine endpoints that show 
clinical benefit.
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Large trials were conducted by enormous efforts of the international NET community 
(3-12). This has provided us with important data. Improvements could include trials 
using a pre-selected patient population. This is already implemented in PRRT, where 
somatostatin-receptor-positive patients are selected for treatment (8). Furthermore, 
sequential multiple assignment randomized trials can be used for hypothesis genera-
tion followed by a confirmatory randomized controlled trial (RCT) (21). In addition, trials 
should be focused on reporting QoL and be of sufficient follow-up duration. For GEP-
NET patients, use of QoL could be of additional importance because OS is generally 
prolonged in this cohort.
The importance of long follow-up was previously demonstrated in a trial in patients with 
anaplastic oligodendrogliomas. OS of adjuvant chemoradiotherapy versus radiotherapy 
was not improved at a median follow-up of 60 months, but was improved in the chemo-
radiotherapy arm at a median follow-up of 140 months (22). 
International collaboration in clinical trials and investigator-driven trials should be further 
expanded to increase evidence based data to support treatment decisions and lead to 
meaningful clinical benefit for GEP-NET patients. 
Although not the aim of our analysis, we found some limitations of the tools. The ESMO-
MCBS downgrades the preliminary score of a trial if no significant improvement of QoL 
data was shown (14). If QoL was not reported, the preliminary score did not have to be 
downgraded (8,9). 
Furthermore, we noticed during the scoring process, a difference in consensus achieved 
by assessing trials according to the ESMO-MCBS, compared to trials assessed ac-
cording to the NHB-ASCO-F. With the ESMO-MCBS for more trials consensus was 
achieved. A possible reason for this is the complex toxicity data reporting according 
to the NHB-ASCO-F. Potentially, a clearer definition of ‘clinical relevant toxicity’ could 
facilitate the scoring. With the ASCO framework, eight clinicians completed the tool for 
11 anticancer drugs. A Cohen’s kappa coefficient of the interrater reliability (ICC) of 0.11 
for NHB and 0.06 for toxicity was found, corresponding with ´slightly reliable agreement’ 
(18).
However in another study where convergent validity and interrater reliability of as-
sessment frameworks were analyzed; the ASCO framework had an ICC of 0.80 (23). 
In another report, 109 RCTs were included and ESMO scores and scores using the 
concept and revised version of the ASCO framework were determined. Weak to moder-
ate correlations were demonstrated, suggesting different constructs of clinical benefit 
measured (24). Other tools, used to define the value and also addressing the costs of 
drugs, include the National Comprehensive Cancer Network evidence blocks, Institute 
for Clinical and Economic Review value assessment framework and Memorial Sloan 
Kettering Drug Abacus (25-27). Every tool has its own aspects. In the future converging 
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of tools is expected which will allow to combine the best aspects of these tools to guide 
policy makers and patient-doctor discussions (28). 
Conclusion 
The ESMO-MCBS and the NHB of ASCO revised framework could be applied, respec-
tively, to only 6 and 9 trials investigating systemic treatments in NET patients. The cur-
rently used systemic treatments for GEP-NET patients had low scores according to the 
NHB-ASCO-F and none could be graded as meaningful clinical beneficial according to 
the ESMO-MCBS. Despite the low incidence of NET, the heterogeneous patient popula-
tion and the relatively long natural course, future studies on new treatment modalities 
should aim for high clinical benefit outcomes. 
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Supplementary Table S1: Eligibility criteria for assessment with ESMO-MCBS and NHB of the revised 
ASCO framework
ESMO-MCBS NHB part of revised ASCO 
framework
Design Comparative outcome studies: (one of these)
• Randomized design 
• Comparative cohort-design 
• Systematic review
New treatment compared with a 
prevailing standard of careA in a well-
designed, well-conducted prospective 
randomized trialB.
Outcome Relative benefit of treatments; (one of these, if 
given as primary endpoint)
• Survival 
• QoL
• Surrogate outcomes for survival or QoL,
• Treatment toxicities
Benefit: (one of these)
• If available -> OS
• If OS data is not available ->PFS
•  If OS and PFS data are not 
available  ->RR
Toxicity Toxicity data 
(Can up- or down grade the final score)
Toxicity data graded in accordance 
with WHO criteria in grade 1,2 and 
grade 3,4. (Can up- or down grade the 
final score)
Disease Solid cancers Advanced disease or potentially 





Results derived from well-powered registration 
trial should be given priority.




These can be scored with a maximum of three 
subgroups, scoring  should be done separately 
when for more than one subgroup statistically 




These are not graded, except for studies that 
incorporate collection of tissue samples to 




(Only if data are 
available)
QoL 
(Can up- or down grade the final score)
Bonus: 
• Tail of the curve
• Palliation 
• QoL
• Treatment free intervalB 
(Can upgrade the final score) 
ASCO= American Society of Clinical Oncology, ESMO-MCBS= European Society of Medical Oncology- Magnitude 
of Clinical Benefit Scale, NA= not applicable, NHB= net health benefit, OS= overall survival, PFS=progression free 
survival, QoL=quality of life, RR=response rate
A) In conceptual framework
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266 Duplicates excluded 
1453 ‘Clearly not relevant’ articles excluded based on 
title and abstract 
39 articles remaining for 
analysis including 35 trials  
 
223 articles 
189 articles excluded based on: 
The clinical question of 43 articles, was published 
later in a better article or with a better trial design.   
  In 83 articles the main subject was not the 
comparison of intervention 
  8  Articles showed only a multivariate analysis 
  1  Article was not only about NET 
  20 Articles were post-hoc analyses, without 
comparison of intervention 
  21 Articles did not have a cohort design, a 
randomized trial design, or a design of a meta-
analysis. 
  7 Articles only showed baseline results or the 
planned study 
  1 Article used an outcome that was not eligible for 
scoring (i.e. blood flow in liver metastases) 





Nog precies natellen 
5 articles with publication date after literature search 
included later,  
  4 Phase III trials,  
 1 post-hoc analysis of predefined quality of life data 
 
Supplementary Figure S1. Inclusion process for the literature analysis
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A B C D E F G H Eligibility criteria that should
Caplin (1)  be met for a valid score:
Meyer (2) Eligibility criteria are 
Pavel (3,4) not met.
Raymond (5) Eligibility criteria are 
Rinke (6,7) partly met.
Strosberg (8) All eligibility criteria 


























A; More than 50% of participants has another NET than a gastro-intestinal or pancreatic NET 
B; Sample size of pre-planned power analysis not reached 
C; Same clinical question evaluated in more studies
D; Toxicity data are not available and graded
E; Outcome data available
F; No prospective, randomized design
G; No randomized, comparative cohort design, or meta-analysis
H; No toxicity data available 
Figure 2. Eligibility criteria for a valid evaluation with the tools
Chapter 2
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Supplementary data; Extensive methods
Search strategy
Trials were searched in the databases PubMed and EMBASE between Aug 1st 2015 to 
Jan 31th 2016. The following search terms were used in various combinations ‘neuroen-
docrine’, ‘tumor’, ‘pNET’, ‘neoplasm’, ‘survival’, ‘disease-free survival’, ‘quality of life’, 
‘QOL’, ‘toxicity’, ‘adverse events’, ‘chemotherapy’, ‘cytostatic’, ‘interferon’, ‘somatostatin 
analogue’, ‘everolimus’, ‘sunitinib’, ‘indium’, ‘lutetium’, ‘peptide receptor radionuclide’, 
‘controlled trial’ and ‘clinical trial’. The articles that were found were screened using title 
and abstract to select trials published in the English language and comparing systemic 
treatment modalities for the treatment of GEP-NET in humans. Furthermore the refer-
ence lists of the European Neuroendocrine Tumor Society (ENETS), National Compre-
hensive Cancer Network, (NCCN) and North American Neuroendocrine Tumor Society 
(NANETS), guidelines were reviewed for comparative trials that support the guidelines 
(suppl ref 27-29). Also reference lists of included trials and conference abstracts were 
reviewed for additional relevant articles. 
Selection criteria for trials
Comparative trials investigating systemic antitumor treatment for GEP-NET patients 
were analyzed. Criteria for assessment are summarized in Table S1. Trials were eligible 
for grading with the ESMO-MCBS if either a randomized or comparative cohort design 
was used or if a meta-analysis was used reporting a statistically significant benefit in 
any of the evaluated outcomes. With the NHB of the revised ASCO framework only 
randomized controlled trials (RCTs) could be graded. Furthermore for both tools only 
well-powered trials evaluating survival, QoL, surrogate outcomes of survival (disease-
free interval, event-free survival, time to response, PFS and time to progression), or 
treatment toxicity could be graded. When more than one trial, that fulfilled the selec-
tion criteria, analyzed the same clinical question, results derived from well powered 
registration trials, prevailed. Trials were selected if at least 50% of participants were 
diagnosed with GEP-NET, and the other participants had a NET of unknown or other 
origin. Abstracts reporting clinical trials in GEP-NET patients were only permitted for 
analysis if they showed additional data to an already published article.
ESMO-MCBS and the NHB of the revised ASCO framework 
ESMO-MCBS grades in the non-curative setting ranges from 1-5, with grade 4 and 5 
representing meaningful clinical benefit. To evaluate different endpoints three forms are 
available; form 2a and 2b for ‘trials with primary endpoint OS’, and ‘PFS’, respectively 
and form 2c for trials with ‘with primary endpoint other than OS or PFS or equivalence 
studies’. The NHB of the revised ASCO framework consists of the clinical benefit score 
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(CBS), (i.e. the hazard ratio or median of OS or PFS, or response rate (RR)) toxicity 
and bonus points (for long term disease control, palliation, treatment free interval and 
QoL). The NHB of the revised ASCO framework ranges from -20 to 180, with a higher 
score representing a better NHB, no cutoff value was provided to define clinical benefit. 
All relevant comparative trials were assessed according to both tools. Relevant trials 
that did not meet all criteria as mentioned in Table 1 were assessed separately, based 
on the available data. 
Assessment of trials
Four members from all Dutch European Neuroendocrine Tumor Society (ENETS) cen-
ters of excellence (Academic Medical Center, Erasmus Medical Center, Netherlands 
Cancer Institute, and University Medical Center Groningen) independently scored the 
trials according to the ESMO-MCBS and the NHB of the revised ASCO framework. 
After obtaining scores of these assessors we noticed a wide variation in results. During 
a consensus meeting additional agreements were defined. Next, trials were assessed 
again according to the additional agreements. The number of trials to which the same 
score was awarded between three or four assessors was registered after each of the 
two scoring sessions. Two phase III trials were published after the consensus meeting 
and were assessed according our agreements. Therefore an additional assessment 
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